Your browser doesn't support javascript.
loading
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.
Qiu, Xintao; Boufaied, Nadia; Hallal, Tarek; Feit, Avery; de Polo, Anna; Luoma, Adrienne M; Alahmadi, Walaa; Larocque, Janie; Zadra, Giorgia; Xie, Yingtian; Gu, Shengqing; Tang, Qin; Zhang, Yi; Syamala, Sudeepa; Seo, Ji-Heui; Bell, Connor; O'Connor, Edward; Liu, Yang; Schaeffer, Edward M; Jeffrey Karnes, R; Weinmann, Sheila; Davicioni, Elai; Morrissey, Colm; Cejas, Paloma; Ellis, Leigh; Loda, Massimo; Wucherpfennig, Kai W; Pomerantz, Mark M; Spratt, Daniel E; Corey, Eva; Freedman, Matthew L; Shirley Liu, X; Brown, Myles; Long, Henry W; Labbé, David P.
Afiliação
  • Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Boufaied N; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Hallal T; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Feit A; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • de Polo A; Department of Anatomy and Cell Biology, McGill University, Montréal, QC, Canada.
  • Luoma AM; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Alahmadi W; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Larocque J; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Zadra G; Division of Urology, Department of Surgery, McGill University, Montréal, QC, Canada.
  • Xie Y; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gu S; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Tang Q; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, QC, Canada.
  • Zhang Y; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Syamala S; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, QC, Canada.
  • Seo JH; Departments of Oncologic Pathology and Pathology, Dana-Farber Cancer Institute and Brigham's Women Hospital, Boston, MA, USA.
  • Bell C; Institute of Molecular Genetics, National Research Council, Pavia, Italy.
  • O'Connor E; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Liu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Schaeffer EM; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jeffrey Karnes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Weinmann S; Department of Data Science, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Davicioni E; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Morrissey C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Cejas P; Department of Data Science, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Ellis L; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Loda M; Department of Data Science, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Wucherpfennig KW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Spratt DE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Corey E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Freedman ML; Decipher Biosciences, San Diego, CA, USA.
  • Shirley Liu X; Department of Urology, Northwestern University, Chicago, IL, USA.
  • Brown M; Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Long HW; Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
  • Labbé DP; Decipher Biosciences, San Diego, CA, USA.
Nat Commun ; 13(1): 2559, 2022 05 13.
Article em En | MEDLINE | ID: mdl-35562350
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Receptores Androgênicos Limite: Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Receptores Androgênicos Limite: Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos